Workshop on Assessing the Impact of Fishing on Oceanic Carbon (WKFISHCARBON; outputs from 2023 meeting)

Rapports Scientifiques du CIEM. Volume 6, nº 12The Workshop on Assessing the Impact of Fishing on Oceanic Carbon (WKFISHCARBON) was set up to provide ICES and stakeholders with a summary of knowledge on the role of fishing in the process of carbon budgets, sequestration and footprint in the ocean. The workshop addressed the potential impact of fishing on the biological carbon pump (BCP), the possible impacts of bottom trawling on carbon stores in the seabed, as well as considering emissions from fishing vessels. The overall aim was to generate proposals on how to develop an ICES approach to fishing and its role in the ocean carbon budget, and to develop a roadmap for a way forward. The main findings were that knowledge of the BCP in the open ocean was reasonably well developed, but that key gaps existed. In particular, information on the biomass of mesopelagic fish and other biota, and of some of the key processes e.g. fluxes and fish bioenergetics. Knowledge is much weaker for the BCP in shelf seas, where the bulk of fishing occurs. In particular, while biomass of fish was often well quantified, unlike the open ocean, the understanding of the important processes was lacking, particularly for the fate of faecal pellets and deadfall at the seabed. There is extensive scientific knowledge of the impact of fishing on the seabed, but what is un-clear is what it means for seabed carbon storage. There have been numbers of studies, which give a very divided view on this. There has also been open controversy about this in the literature. Physical disturbance to the seabed from fishing can affect sediment transport and has the potential to facilitate remineralization, but precise impacts will depend on habitat, fishing métier, and other environmental factors. From this, it is clear that more research is needed to resolve the controversy, and to quantify the impacts from different fishing gears and on different substrates or habitats in terms of carbon storage. There has been much more research on minimizing fuel use by fishing vessels, and hence emissions, but this has mainly focused on fuel efficiency, fuel use per unit of landed catch, and less on the total emissions. Baselines for fuel use are available at the global level, but are lacking at the national and vessel level. There is a need for standardization of methodologies and protocols, and for improving the uptake of fuel conservation measures by industry, as well as for improving the uptake of existing and potential fuel conservation and efficiency measures by industry. Finally, a roadmap was proposed to develop research and synthesis, on the understandings of the processes involved, the metrics and how to translate this into possible advice for policy-makers. To that end, a further workshop was proposed in 2024.info:eu-repo/semantics/publishedVersio

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival

Goethite Nanorods: Synthesis and Investigation of the Size Effect on Their Orientation within a Magnetic Field by SAXS

Goethite is a naturally anisotropic, antiferromagnetic iron oxide. Following its atomic structure, crystals grow into a fine needle shape that has interesting properties in a magnetic field. The needles align parallel to weak magnetic fields and perpendicular when subjected to high fields. We synthesized goethite nanorods with lengths between 200 nm and 650 nm in a two-step process. In a first step we synthesized precursor particles made of akaganeite (β-FeOOH) rods from iron(III)chloride. The precursors were then treated in a hydrothermal reactor under alkaline conditions with NaOH and polyvinylpyrrolidone (PVP) to form goethite needles. The aspect ratio was tunable between 8 and 15, based on the conditions during hydrothermal treatment. The orientation of these particles in a magnetic field was investigated by small angle X-ray scattering (SAXS). We observed that the field strength required to trigger a reorientation is dependent on the length and aspect ratio of the particles and could be shifted from 85 mT for the small particles to about 147 mT for the large particles. These particles could provide highly interesting magnetic properties to nanocomposites, that could then be used for sensing applications or membranes

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaAdjuvant Pembrolizumab in High-Risk Melanoma

We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up to three years (654 patients), the approved standard-of-care adjuvant immunotherapies at the time of enrollment for patients with high-risk resected melanoma. At a median follow-up of 47.5 months, pembrolizumab was associated with significantly longer RFS than prior standard-of-care adjuvant immunotherapies [HR, 0.77; 99.62% confidence interval (CI), 0.59-0.99; P = 0.002]. There was no statistically significant association with OS among all patients (HR, 0.82; 96.3% CI, 0.61-1.09; P = 0.15). Proportions of treatment-related adverse events of grades 3 to 5 were 19.5% with pembrolizumab, 71.2% with IFNα-2b, and 49.2% with ipilimumab. Therefore, adjuvant pembrolizumab significantly improved RFS but not OS compared with the prior standard-of-care immunotherapies for patients with high-risk resected melanoma.SignificanceAdjuvant PD-1 blockade therapy decreases the rates of recurrence, but not survival, in patients with surgically resectable melanoma, substituting the prior standard-of-care immunotherapies for this cancer. See related commentary by Smithy and Shoushtari, p. 599. This article is highlighted in the In This Issue feature, p. 587